Eli Lilly and Co.

Lilly reveals plans to cut 340 IT jobs

July 15, 2010
J.K. Wall
The Indianapolis-based drugmaker eliminated 140 information technology jobs in June through retirements, resignations and some cuts. Another 115 cuts will be made this month, and the remainder by the end of the year.
More

Lilly, Roche dive deep into diagnostics

July 14, 2010
J.K. Wall
Two Indianapolis giants—Eli Lilly and Co. and Roche Diagnostics—are working hard to pair up drugs and diagnostic tests to gin up more sales.
More

Lilly's Alzheimer's gamble takes aim at $10 billion in patent losses

July 13, 2010
Bloomberg News
Both of Lilly's late-stage treatments are designed to reduce plaque in the brain called beta amyloid, thought by researchers to be a main contributor to Alzheimer's. A drug that stops or reduces memory loss caused by Alzheimer's may be worth more than $5 billion a year, an analyst says, helping Lilly overcome the coming patent losses on several important pharmaceuticals.
More

Lilly to cut 170 manufacturing jobs by year's end

July 12, 2010
J.K. Wall
Eli Lilly and Co. will cut 170 jobs—mostly in Indianapolis—from its manufacturing and quality division by the end of the year as it continues its efforts to slim down before losing revenue from patent expirations on its bestselling drugs.
More

Diagnostics division to help Lilly tailor treatmentsRestricted Content

July 10, 2010
J.K. Wall
Eli Lilly and Co. is launching a diagnostics division to produce tests that can winnow out the patients most likely to benefit from a Lilly drug.
More

Lilly's Lechleiter: No change in plans

July 7, 2010
J.K. Wall
The global financial press keeps asking John Lechleiter for his end-game strategy to survive Eli Lilly and Co.'s nightmarish patent challenges. And, like a broken record, the Lilly CEO keeps giving the same answer: pipeline, pipeline, pipeline—no mega-merger.
More

Men on Viagra, Cialis show triple rate of sex diseases in study

July 6, 2010
 IBJ Staff and Bloomberg News
The findings suggest that users of drugs to treat erectile dysfunction, including Eli Lilly's Cialis, may be more likely to engage in unsafe sex than nonusers.
More

Lilly acquires biotech company with pancreatic drug

July 2, 2010
J.K. Wall
Massachusetts-based Alnara Pharmaceuticals Inc., which has attracted $55 million in venture capital in the past two years, recently submitted its drug to the FDA for market approval.
More

Grassley asks Lilly, peers about whistleblower treatment

July 1, 2010
Bloomberg News
U.S. Senator Charles Grassley asked 16 drugmakers, including Eli Lilly & Co., Pfizer Inc. and AstraZeneca Plc, to reveal how they treat whistleblowers who file complaints under the False Claims Act.
More

Lilly's Effient steps forward, then back

June 30, 2010
J.K. Wall
A day after doctors were alerted to a black-box warning that could slow sales of Effient’s main competitor, Plavix, a medical journal published research showing that patients suffered 43-percent more cancer tumors on Effient than on Plavix.
More

Marcadia enlists Lilly to help develop new diabetes drug

June 28, 2010
J.K. Wall
The two companies will jointly develop a short-acting glucagon drug, which they hope proves more convenient than Lilly’s current Glucagon for patients with severe hypoglycemia.
More

Hoosier firms that rely on innovation pine for patent reform

June 26, 2010
J.K. Wall
One key change would grant patents to the first inventor to file an application, not the first who can prove to have made the invention first.
More

Lilly layoffs pare communications department

June 21, 2010
J.K. Wall
The giant drugmaker is in the process of trimming 35 percent—or about 19 people—from its 55-person communications staff. Most of that staff is based in Indianapolis.
More

Recession hammered revenue of Indiana's largest public companies

June 19, 2010
Marc D. Allan
Few escaped the Great Recession unscathed, and unusual circumstances helped some appear as though they did.
More

Slow economy bruises profits of Indiana's largest public companiesRestricted Content

June 19, 2010
Marc D. Allan
One-time events influenced bottom lines of some of the few companies that made more money in 2009.
More

Lilly, Amylin stock rises on drug postponement

June 18, 2010
 IBJ Staff and Bloomberg News
Roche Holding AG's decision to postpone its experimental diabetes drug is helping boost shares in Amylin Pharmaceuticals Inc. and drug partner Eli Lilly and Co.
More

Research reforms will force Lilly, others to test how drugs stack upRestricted Content

June 12, 2010
J.K. Wall
The federal government is currently doling out $1.1 billion in stimulus funds to pay for research that compares multiple medical treatments against one another to determine which is most effective. Drug companies like Eli Lilly and Co. are wary that comparative-effectiveness research could threaten their sales.
More

Lilly taps O'Connor as state lobbyist

June 9, 2010
J.K. Wall
O’Connor, chief deputy mayor under former Indianapolis Mayor Bart Peterson, started Monday as Lilly's director of state government affairs—working again under Peterson.
More

Erbitux fails to stop colon cancer before it spreads

June 6, 2010
Bloomberg News
Eli Lilly and Co. and Merck KGaA drug failed to slow tumors in a study designed to expand the medicine's use to patients whose disease is in an earlier stage.
More

Genetic testing could spur Erbitux drug sales

June 1, 2010
Bloomberg News
The drugmakers are counting on screening for the so-called K-ras gene to spur use of Erbitux in metastatic colorectal cancer.
More

Lilly grows Alimta's sales by shrinking marketRestricted Content

May 29, 2010
J.K. Wall
In 2008, Eli Lilly and Co. asked drug regulators to change the label on Alimta so Lilly could no longer promote it as a treatment for all patients suffering from non-small-cell lung cancer, but for only about 70 percent of the patients. Since then, sales of the drug have accelerated, growing a whopping 48 percent last year.
More

Indianapolis startup attacks Alzheimer's diseaseRestricted Content

May 29, 2010
Norm Heikens
AgeneBio Inc. this month landed a $300,000 investment from the Indiana Seed Fund to fund operations, bolster its intellectual property, and begin learning how to make a drug into a once-a-day pill.
More

Eli Lilly invests in $250M Australian venture fund

May 20, 2010
 IBJ Staff and Bloomberg News
The unnamed venture fund will be based in Brisbane, and will focus on biotechnology investments in Australia and southeastern Asia.
More

Drug-spending increase highest in four years

May 20, 2010
Bloomberg News
The price increase was fueled by the debate over the health-care overhaul in Washington, D.C., Medco Health Solutions Inc. CEO David Snow said.
More

Lilly, others cut U.S. tax bills through transfer pricing

May 14, 2010
Bloomberg News
U.S. companies, including Eli Lilly, amassed at least $1 trillion in foreign profits not taxed in the U.S. as of the end of last year. That cumulative total increased 70 percent over three years.
More
Page  << 11 12 13 14 15 16 17 18 19 20 >> pager
Sponsored by
ADVERTISEMENT

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
 
Subscribe to IBJ
ADVERTISEMENT